Analysts Set LifeMD, Inc. (NASDAQ:LFMD) Target Price at $12.00

LifeMD, Inc. (NASDAQ:LFMD) has earned a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.00.

A number of analysts have recently weighed in on the company. B. Riley assumed coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 price target on the stock. KeyCorp dropped their target price on LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price target on shares of LifeMD in a research report on Tuesday, August 20th.

LifeMD Stock Performance

Shares of LFMD opened at $5.28 on Friday. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. LifeMD has a 12-month low of $4.05 and a 12-month high of $12.88. The business’s fifty day moving average price is $5.74 and its 200 day moving average price is $7.85. The stock has a market capitalization of $220.48 million, a PE ratio of -7.14 and a beta of 1.19.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to analyst estimates of $48.47 million. During the same period in the previous year, the business earned ($0.23) earnings per share. Equities research analysts forecast that LifeMD will post -0.49 EPS for the current year.

Institutional Trading of LifeMD

Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new position in shares of LifeMD during the second quarter valued at $31,000. EntryPoint Capital LLC acquired a new position in LifeMD during the 1st quarter valued at about $89,000. Los Angeles Capital Management LLC acquired a new position in LifeMD during the 2nd quarter valued at about $88,000. The Manufacturers Life Insurance Company bought a new stake in shares of LifeMD during the 2nd quarter worth about $93,000. Finally, XTX Topco Ltd acquired a new stake in shares of LifeMD in the 2nd quarter worth approximately $94,000. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.